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Abstract
Background: Aspergillus is a ubiquitous soil-dwelling fungus known to cause significant pulmonary
infection in immunocompromised patients. The incidence of aspergillosis has increased during the
past two decades and is a frequently lethal complication of acute leukemia patients that occurs
following both chemotherapy and bone marrow transplantation. The diagnosis of invasive
pulmonary aspergillosis (IPA) according to the criteria that are established by European
Organization for the Research and Treatment of Cancer and Mycoses Study Group raise difficulties
in severely ill patients. Despite established improvements in field of diagnosis (galactomannan
antigen, quantitative PCR, real-time PCR for Aspergillus spp., and findings of computed tomography)
and treatment with new antifungals, it is still a major problem in patients with acute leukemia.
However, prompt and effective treatment of IPA is crucial because most patients will need
subsequent chemotherapy for underlying hematologic disease as soon as possible.
Case presentation: We report a 33-year-old male patient with acute promyelocytic leukemia
diagnosed in 1993 that developed invasive pulmonary aspergillosis due to A. flavus at relapse in
2003. The patient was successfully treated with liposomal amphotericin B and underwent surgical
pulmonary resection. The operative course was uneventful.
Conclusion:  This report emphasizes the clinical picture, applicability of recent advances in
diagnostic and therapeutic approaches for IPA. For early identification of a patient infected with
IPA, a high index of suspicion and careful clinical and radiological examinations with serial screening
for galactomannan should be established. If aspergillosis is suspected, anti-aspergillosis drug should
be administered immediately, and if a unique pulmonary lesion remains, surgical resection should
be considered to prevent reactivation during consecutive chemotherapy courses and to improve
the outcome.
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Background
Aspergillus is a ubiquitous soil-dwelling fungus known to
cause significant pulmonary infection in immunocom-
promised patients. The incidence of aspergillosis has
increased during the past two decades due to widespread
use of chemotherapy and immunosuppressive agents, and
is a frequently lethal complication of acute leukemia
patients that occurs following both chemotherapy and
bone marrow transplantation (BMT) [1]. The mortality
rate reaches 50% for chemotherapy-induced neutropenia
and can exceed 90% in BMT patients [2,3]. Early diagnosis
and treatment of infection are crucial, however, definite
diagnosis is not straight-forward and requires invasive
procedures that are often difficult or impossible due to
bleeding tendency or poor condition of patient, and the
diagnostic yield of bronchoalveolar lavage, including
cytology and fungal culture, is low. Despite established
improvements in field of diagnosis (galactomannan anti-
gen (GM), quantitative PCR, real-time PCR for Aspergillus
spp., and findings of computed tomography) and treat-
ment, it is still a major problem in patients with acute
leukemia [4-6]. Recently, because of the difficulties in
diagnosis of IPA, the European Organization for Research
and Treatment of Cancer (EORTC) Invasive Fungal Infec-
tions Cooperative Group and the Mycoses Study Group
(MSG) of the National Institute of Allergy and Infectious
Disease established consensus definitions for defining
opportunistic invasive fungal infections [7]. Although, the
EORTC/MSG criteria are important in the standardization
of definitions used for IPA in clinical research studies, it
does not demonstrate the true incidence of IPA in hema-
tologic patients [8,9], and it does not include the non-cul-
ture-based diagnostic techniques. However, rapid and
effective treatment of IPA is important because most
patients will need subsequent chemotherapy for the
underlying hematologic disease as soon as possible
[10,11]. Given the lack of diagnostic certainty, and mor-
tality and morbidity rate associated with IPA, empirical
initiation of antifungal has been recommended for neu-
tropenic patients with fever who do not respond to broad-
spectrum antibiotics [5,10,12]. There are several studies
indicating that antifungal treatment in combination with
surgery improves survival in patients with acute leukemia,
and lung tissue resection led to clearance of disease in
72% to 100% of patients [13]. A surgical procedure,
excluding emergency operation for massive hemopthysis,
is mainly used for either resection of a localized nodule or
nodules that persist despite antifungal treatment or to pre-
vent massive pulmonary hemorrhage that might be fatal
or to eradicate residual fungal foci prior to further chemo-
therapy or BMT [3,14].
We report a case of acute promyelocytic leukemia that
complicated with IPA due to A. flavus at relapse in 2003 10
years after initial diagnosis, and who was successfully
treated with liposomal amphotericin B (L-AmB) by a
combination of surgical resection. This report emphasizes
the clinical picture and applicability of recent advances in
the diagnostic and therapeutic approaches for IPA.
Case presentation
Acute promyelocytic leukemia (AML-M3, APL) was diag-
nosed in a 33-year-old male in August 1993 who was suc-
cessfully treated with doxorubicin and cytosine
arabinoside (ARA-C). In July 2003, a second relapse of
leukemia was established and the patient achieved com-
plete hematologic remission following induction chemo-
therapy. He then received consolidation chemotherapy.
In neutropenic period, he developed first neutropenic
fever that resolved with broad spectrum antibiotics. But,
fever recurred and he developed signs of respiratory fail-
ure with tachypnea. Chest X-ray showed pulmonary infil-
tration in the left lower lobe. Intravenous broad spectrum
antibiotics were started, and on day 3 of the beginning of
respiratory symptoms, intravenous L-AmB (1 mg/kg/day)
was added as an antifungal therapy. Aspergillus was not
cultured from his sputum, and galactomannan antigen
(GM), (Platelia® Aspergillus; Bio-Rad Laboratories, France)
and blood culture were negative. Testing for Aspergillus
antigenemia presented positivity and L-AmB dose was
increased to 3 mg/kg/day, on day 6. At that time, high-res-
olution computed tomography (HRCT) showed the pres-
ence of pulmonary infiltrates in the left and right superior
lobes and a cavity in the left lower lobe (Figure 1A,B).
Thereafter, his respiratory condition improved and fever
resolved within three days, and he recovered from neutro-
penia without use of granulocyte colony stimulating fac-
tor a week later. On day 11, a chest X-ray demonstrated
reduction of pulmonary infiltrates, however the cavitary
lesion persisted. After informed consent of the patient was
obtained he underwent surgical treatment under general
anesthesia on day 20. There was no adhesion in the tho-
racic cavity. The lesion was easily identified and pulmo-
nary wedge resection was performed (Figure 1C,D). The
operative course was uneventful and blood loss was
minor. Aspergillus flavus was cultured and many Aspergillus
hyphae were demonstrated within the surgical specimen.
In January 2004, a third relapse of leukemia was estab-
lished. He again underwent induction and further chem-
otherapies, and then, in February 2005, he received
allogeneic stem-cell transplantation. These procedures
were established without IPA reactivation and he had no
side effect thought to be secondary to pulmonary resec-
tion. However, three months after stem-cell transplanta-
tion, he died due to intracerebral hemorrhage.
Discussion
Aspergilli  are ubiquitous in the environment and more
than 180 species of Aspergillus have been identified; how-
ever only few are considered as pathogenetic in humanAnnals of Clinical Microbiology and Antimicrobials 2006, 5:17 http://www.ann-clinmicrob.com/content/5/1/17
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beings, notably A. fumigatus, A. flavus, A. niger, A. terreus
and A. nidulans. Aspergillus fumigatus, a conidium of 1–3
µm in diameter, is the most common frequent species
found in 90% of infections. It is carried by air and over-
comes the defensive abilities of upper respiratory tract and
penetrates up to distal alveolar spaces. Thereafter, it ger-
minates into angioinvasive filamentous hyphae that pro-
duce local tissue damage, hemorrhage, infarction and
coagulative necrosis [6,15-17].
IPA generally presents as an acute infection. Sudden onset
of shortness of breath, pleuritic chest pain, hemopthysis,
pulmonary infiltrates, and fever un-responsive to broad-
spectrum antibiotics constitute the characteristic clinical
picture of the disease [15,16]. Early diagnosis of IPA
remains difficult mainly because clinical signs and symp-
toms are not specific, culture and microscopy of lower res-
piratory tract specimens have low sensitivity, and
histopathological examination of infected tissue is not
(A) Chest X-ray, (B) CT scan of the chest: a cavitary lesion showing an "air-crescent shadow" in the left lower lobe, (C, D)  Resected pulmonary cavitary specimen without fungus ball Figure 1
(A) Chest X-ray, (B) CT scan of the chest: a cavitary lesion showing an "air-crescent shadow" in the left lower lobe, (C, D) 
Resected pulmonary cavitary specimen without fungus ball.
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easy due to often-poor condition and underlying coagula-
tion abnormalities of patient [15]. Chest radiograph find-
ings are not sensitive and specific for IPA, and also it may
be normal in up to 10% [6]. HRCT scan is the most sensi-
tive radiological method to detect early changes of IPA.
"Halo sign" which correlates with hemorrhage and edema
surrounding an infarct by thrombosis occurs early in the
course of infection and is highly suggestive of IPA in
patients with neutropenia and leukemia [6,15-17]. Air
crescent sign, which is a central necrotic nodule with cir-
cumferential air density, develops mainly at the time of
BM recovery. A cavitary lesion is the late stage of IPA. But,
both halo sign and air crescent sign are not pathogno-
monic for aspergillosis and they can also be found in
other fungal, as well as bacterial infections and other pul-
monary disorders [12,15,17]. Recently, because of the dif-
ficulties in diagnosis of IPA, the European Organization
for Research and Treatment of Cancer (EORTC) and Inva-
sive Fungal Infections Cooperative Group and the
Mycoses Study Group (MSG) of the National Institute of
Allergy and Infectious Disease established consensus def-
initions for defining opportunistic invasive fungal infec-
tions based on a combination of host factors, clinical
manifestations, and mycological results (Table 1) [7].
However, recently, Subira et al [8] studied the clinical
applicability of EORTC/MSG classification in 22 patients
with hematological malignancies who had IPA at autopsy
and found that while alive, according to the EORTC/MSG
criteria, only 2 patients had proven IPA, 6 probable, 13
possible and 1 was unclassifiable.
One noninvasive tool currently applied to the diagnosis
of invasive aspergillosis (IA) is GM, a major aspergillar
cell-wall constituent, which is released during invasive
disease. Serial screening for GM, complemented by appro-
priate radiologic techniques, can help to establish an early
diagnosis of IPA in neutropenic patients with leukemia.
Antigenemia can precede the diagnosis of IA by 8 and 9
days in 80% and 88.8% of patients, respectively. How-
ever, the optimal threshold for positivity remains a matter
of debate [12,18]. Furthermore, there are still several
problems in its applicability because of false-positive and
false-negative reactions reported [15]. The case that we
presented was a patient with high-risk acute myeloid
leukemia (AML-M3, or APL) who underwent chemother-
apy due to a second relapse after 10 years following diag-
nosis, with an occurrence of patchy pulmonary infiltrates
and, subsequently, pulmonary cavitation due to A. flavus
infection during consolidation therapy. We actually
believe that our patient is a well case of IPA regarding dif-
ficulties in diagnosis of IPA, negative clinical applicability
of EORTC/MSG criteria, and both positive and false-nega-
tive applicability of Aspergillus  antigenemia in practice.
Our patient can be classified as possible IPA according to
the EORTC/MSG criteria, but it was demonstrated that he
had true IPA. The patient was under the Aspergillus antigen
testing for two times per week from the day of deep neu-
tropenia; however GM positivity (cut-off index ≥ 1) was
observed six days after the beginning of respiratory symp-
toms. The negativity of antigenemia might be due to the
use of empirical L-AmB therapy. Nonetheless, GM index ≥
1 warranted us to increase the dose of anti-Aspergillus ther-
apy. Because we could not perform early HRCT evalua-
tion, we did not observe halo sing in our patient. We
observed a cavitary lesion showing an "air-crescent
shadow" in the left lower lobe, which was the sign of BM
recovery.
The optimal therapeutic management of IPA is controver-
sial, ranging from different antifungal drugs to additional
lung resection. Amphotericin B deoxycholate (AmB) has
been used for many years as drug of choice for the treat-
ment of IPA. The newer therapeutic options include: a)
lipid formulations of AmB; b) azole antifungals, with
anti-Aspergillus activity, itraconazole, and the third gener-
ation azole drugs, voriconazole, ravuconazole, posacona-
zole; and c) caspofungin, which belongs to a new class of
antifungals, the echinocandines. Response to antifungal
therapy in patients with acute leukemia complicated with
IPA is highly individualized and depends on immune sta-
tus, extent of disease and tolerability of drugs, and the
prognosis is poor if the neutrophile count does not
recover [15,19]. In our patient, we administered L-AmB at
a dose of 1 mg/kg/day because of negative criteria for IPA.
L-AmB is the only true liposomal formulation and admit-
ted empiric treatment for febrile neutropenia resisting
antibiotics as it has been tested in various clinical trials
and proved to be effective and safe [20-23]. Although,
Ellis et al [24] in an EORTC international multicenter ran-
domized trial (EORTC number 19923) in which neutro-
penic patients with cancer or those undergoing BMT
compared two dosages of L-AmB (1 mg/kg/d versus 4 mg/
kg/d) found that a 1 mg/kg/d dosage was as effective as 4
mg/kg/d dosage, generally the recommended dose regi-
Table 1: EORTC/MNG criteria for definition of IPA
Type of IPA Criteria
Proven Demonstration of fungus in tissue histopathology or positive culture of tissue obtained by invasive procedure
Probable One host factor plus one clinical feature plus one mycological factor
Possible one host factor plus two minor clinical feature or one major clinical factorAnnals of Clinical Microbiology and Antimicrobials 2006, 5:17 http://www.ann-clinmicrob.com/content/5/1/17
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men of L-AmB is 3–5 mg/kg/d [25]. In our case, L-AmB
which was increased to the dose of 3 mg/kg/d when the
GM test became positive was found to be effective for IPA
due to A. flavus. We were not able to administer one of the
recent molecules (voriconazole or caspofungin), because
in 2003 these drugs were not licensed in our country. New
antifungal agents (voriconazole and caspofungin) were
found to lead to better responses and improved survival
and fewer side effects when compared with AmB as an ini-
tial therapy [26,27]. In several studies voriconazole and
caspofungin were compared with L-AmB as empirical
antifungal therapy in patients with febrile neutropenia,
and it was shown that these drugs were non-inferior to L-
AmB [22,26-28].
Administration of antifungal therapy and recovery of cir-
culating neutrophils limit the infection, which then fol-
lows a subacute clinical course. At this stage, the involved
area may cavitate and localize to a smaller, more discrete
area [29]. Aspergillus has a characteristic tropism for the
vascular wall and with marrow recovery; white blood cells
lead to necrosis and increase the risk of hemorrhage by
arterial perforation [3]. Also, the persisted cavitary lesion
(as in our case) requires administration of anti-fungal
therapy for several weeks before it disappears. So, surgical
resection of the cavitary lesion may be necessary if treat-
ment of the acute leukemia requires another chemothera-
peutic regimen because of the high-risk of reactivation of
Aspergillosis and massive hemoptysis with likelihood of
death [2,3,19,30-33]. In this setting, a lobectomy, a seg-
mentectomy, or a wedge resection, depending on the loca-
tion and size of the aspergillosis lesion may be required
[3]. In our patient, the clinical course evolved into a sub-
acute form of aspergillosis due to neutrophile recovery
and possibly, as a result of promptly initiated antifungal
therapy. Because of the necessity for continuing therapy
against leukemia, as well as the difficulty of eradicating
aspergillosis in cavitary lesions and preventing aspergillo-
sis reactivation, the solitary lesion in his left lung was
resected. The surgical treatment was performed at 20th
day, because previous condition of the patient was not
suitable for operation due to coagulation abnormalities.
We did not observe an infectious, hemorrhagic or another
complication related to general anesthesia and surgical
intervention. This procedure made consecutive therapies
safe and timely.
In conclusion, for early identification of a patient infected
with IPA, a high index of suspicion and careful clinical
and early radiological examinations with serial screening
for GM should be established, and prompt administration
of antifungal agents to improve the outcome of IPA
should be considered. Finally, the combination of anti-
fungal agents with surgical resection is an efficient and
may be a cost effective strategy to eliminate residual pul-
monary lesions for the treatment of IPA and to permit
completion of therapies in patients with acute leukemia.
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